Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand

Today’s guest post comes from Michael Harris, Vice President of Patient Support Services Strategy at Valeris.

Michael explores the rise of medical benefit maximizers as a new—and often overlooked—force shaping patient access. He outlines how these strategies can erode access, absorb support dollars, and introduce hidden risks for brands.

To learn more about Valeris’ technology solutions and data analytics capabilities, connect with Valeris.

Read on for Michael’s insights

Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand
By Michael Harris, Vice President, Patient Support Services Strategy, Valeris

While the life sciences industry has spent years unpacking the implications of copay accumulators and pharmacy benefit maximizers, a new frontier in benefit design is quietly taking shape: medical benefit maximizers. These strategies are becoming more prevalent within medical plans, yet many manufacturers and patient services teams do not fully recognize their prevalence or practical impact.

Industry analysts have documented that accumulators and maximizers are no longer theoretical policy issues. They are operational realities affecting payers, providers, patients, and manufacturers. Plans use these designs to influence patient cost sharing and shift financial risk, often in ways that leave patients with higher out-of-pocket costs while obscuring the true cost of therapy access.

Why This Matters for Manufacturers and Patient Access

Data and industry commentary highlight the growing penetration of accumulator and maximizer programs and the structural challenges they pose. Plans’ increasing use of these designs reflects benefit strategies that prioritize financial engineering over transparency.

For manufacturers, the implications are twofold:

• Patient access can erode as patients encounter unexpected financial obligations or administrative barriers tied to these benefit designs.


• Support program investments can be diluted when maximizer tactics absorb manufacturer assistance dollars without producing measurable patient outcomes.

Is Your Brand Impacted?

Valeris has identified over 200 brands currently targeted under medical benefit maximizer plans. If your brand appears on this list and your copay or patient services provider has not addressed these emerging tactics, it is time to take action.

“Medical benefit maximizers are reshaping how patients access therapy, and brands that have not assessed exposure risk facing avoidable disruptions,” said Michael Harris, Vice President of Patient Support Services Strategy at Valeris. “Review the list, understand where your brand stands, and act now. Waiting could put both patients and program performance at risk.”

Brand leaders should take a hard look at their current patient services strategies. If your provider has not raised this issue proactively, that is a clear signal to evaluate whether your approach is fully equipped to address these emerging payer tactics.

So, What Is Next?

Click here to download the full list of impacted brands to determine whether your brand is affected. If your copay or patient services provider has not raised this issue, it is critical to take action now. Manufacturers can reach out to the Valeris Patient Affordability team to uncover emerging payer tactics, assess exposure, and implement proactive strategies to safeguard both patient access and brand performance.

Click here to connect with our team.

---

Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).